TY - JOUR AB - Lipid metabolism dysfunction and inflammatory infiltration into arterial walls are associated with the initiation and progression of atherosclerosis. Luteolin has been reported to possess anti‑inflammatory actions and protect against tumor necrosis factor‑α (TNF‑α)‑induced vascular inflammation, monocyte adhesion to endothelial cells and the formation of lipid‑laden macrophages in vitro. However, the role of luteolin in atherosclerosis and the associated vascular inflammatory remains to be elucidated. The aim of the present study was to investigate the effects of luteolin on plaque development, lipid accumulation and macrophage inflammation low‑density lipoprotein receptor‑deficient (LDLR‑/‑) mice with atherosclerosis, as well as the underlying mechanisms in ox‑induced THP‑1‑derived macrophages. Firstly, 9‑week‑old male C57BL/6 mice were fed a standard chow diet, western diet or western diet supplemented with 100 mg/kg luteolin for 14 weeks. The results of histological staining revealed that 100 mg/kg dietary luteolin ameliorated western diet‑induced atherosclerotic plaque development and lipid accumulation in the abdominal aorta. Furthermore, total cholesterol, triglyceride and LDL‑cholesterol levels were decreased in the plasma of western diet + luteolin mice compared with those fed with a western diet alone. Quantitative polymerase chain reaction analysis revealed that dietary luteolin inhibited the expression of cluster of differentiation 68, macrophage chemoattractant protein 2 and inflammatory cytokines, including interleukin‑6 (IL‑6) and TNF‑α. Mechanistically, luteolin decreased the total cholesterol level as well as macrophage chemokine and inflammatory cytokine expression in THP‑1‑derived macrophages via AMP‑activated protein kinase (AMPK)‑Sirtuin (SIRT)1 signaling following induction with oxidized low‑density lipoprotein. The results of the present study suggest that luteolin prevents plaque development and lipid accumulation in the abdominal aorta by decreasing macrophage inflammation during atherosclerosis, which is mediated by mechanisms including AMPK‑SIRT1 signaling. AD - Department of Cardiology, Beijing An Zhen Hospital, Capital Medical University, Beijing 100029, P.R. China Department of Rheumatology, Beijing An Zhen Hospital, Capital Medical University, Beijing 100029, P.R. China AU - Li,Jiang AU - Dong,Jian‑Zeng AU - Ren,Yan‑Long AU - Zhu,Jia‑Jia AU - Cao,Jia‑Ning AU - Zhang,Jing AU - Pan,Li‑Li DA - 2018/09/01 DO - 10.3892/etm.2018.6499 EP - 2599 IS - 3 JO - Exp Ther Med KW - luteolin atherosclerosis aorta lipid accumulation macrophage PY - 2018 SN - 1792-0981 1792-1015 SP - 2593 ST - Luteolin decreases atherosclerosis in LDL receptor‑deficient mice via a mechanism including decreasing AMPK‑SIRT1 signaling in macrophages T2 - Experimental and Therapeutic Medicine TI - Luteolin decreases atherosclerosis in LDL receptor‑deficient mice via a mechanism including decreasing AMPK‑SIRT1 signaling in macrophages UR - https://doi.org/10.3892/etm.2018.6499 VL - 16 ER -